Continuing Education Activity

Takotsubo cardiomyopathy, also known as stress-induced cardiomyopathy, is a transient form of left ventricular systolic dysfunction that often mimics acute coronary syndrome but occurs in the absence of obstructive coronary artery disease. This condition is frequently triggered by intense emotional or physical stress and is characterized by dynamic electrocardiographic changes, modest elevations in biomarkers, and distinctive patterns of ventricular wall motion abnormalities. Although most patients recover, the condition can be associated with significant complications, including arrhythmias, heart failure, thromboembolism, and cardiogenic shock. This activity provides clinicians with a comprehensive, evidence-based review of the etiology, pathophysiology, clinical presentation, diagnostic criteria, and management strategies for Takotsubo cardiomyopathy. Participants enhance their ability to differentiate this condition from acute coronary syndromes, interpret key diagnostic findings, recognize complications, and implement appropriate multidisciplinary management to optimize patient outcomes.

Objectives:

• Apply evidence-based strategies to diagnose and manage Takotsubo cardiomyopathy across emergency, inpatient, and outpatient settings, incorporating current guideline-directed medical therapy and supportive care.
• Differentiate characteristic electrocardiographic changes, biomarker patterns, and regional wall motion abnormalities, including apical ballooning and variant forms.
• Implement evidence-based management steps towards the treatment of Takotsubo cardiomyopathy.
• Select appropriate pharmacologic and nonpharmacologic therapies while facilitating effective communication and collaboration among cardiology, primary care, critical care, and mental health professionals to optimize coordinated, patient-centered outcomes.

Introduction

Takotsubo cardiomyopathy, also known as transient apical ballooning syndrome, apical ballooning cardiomyopathy, stress-induced cardiomyopathy, stress cardiomyopathy, Gebrochenes-Herz syndrome, and broken-heart syndrome, is a form of nonischemic cardiomyopathy that predominantly affects postmenopausal women.[1][2][3][4][5] This condition is characterized by transient regional systolic dysfunction of the left ventricle in the absence of angiographically significant coronary artery disease or acute plaque rupture. In most cases of Takotsubo cardiomyopathy, the abnormal motion of the heart’s wall extends beyond the area supplied by a single epicardial coronary artery. The term "takotsubo" is derived from Japanese and refers to an octopus trap, whose shape resembles the systolic apical ballooning of the left ventricle (see Image. Takotsubo Cardiomyopathy).

Etiology

The exact etiology of Takotsubo cardiomyopathy remains incompletely defined, and it is best conceptualized as a multifactorial syndrome arising from a convergence of neurohormonal, vascular, and myocardial metabolic derangements. The most widely supported hypothesis centers on sympathetic overdrive with excessive catecholamine release, which is thought to exert direct myocardial toxicity, induce transient myocardial stunning, and contribute to characteristic regional wall motion abnormalities. Additional proposed mechanisms include epicardial coronary artery spasm, coronary microvascular dysfunction leading to impaired myocardial perfusion, systemic and myocardial inflammatory responses, and abnormalities in myocardial energy utilization, particularly impaired fatty acid metabolism. Hormonal influences, particularly reduced estrogen levels, are also implicated and may help explain the marked predominance of this condition in postmenopausal women. Collectively, these mechanisms likely interact rather than operate in isolation, producing the transient but often profound ventricular dysfunction characteristic of the syndrome.

Clinically, Takotsubo cardiomyopathy is strongly associated with identifiable stressors, reinforcing the central role of neurocardiogenic pathways in its pathogenesis. Both emotional and physical triggers have been well described, including domestic abuse, death of relatives, natural disasters, major trauma, interpersonal conflict, financial or gambling loss, and acute medical illness. Stimulant use, such as cocaine or amphetamines, has also been implicated.

Notably, positive emotional stressors may precipitate the condition, a phenomenon termed “happy heart syndrome.” The clinical presentation frequently mimics acute coronary syndrome, often following an acute stress event such as the unexpected death of a loved one, significant confrontation, or a new medical diagnosis.[6] Data from the International Takotsubo Registry further highlight this association, with emotional triggers identified in approximately 27.7% of patients and physical stressors, such as infection or respiratory failure, in about 36% of patients. Combined emotional and physical triggers were present in 7.8% of cases. In comparison, no clear precipitant was identified in approximately 28.5% of cases, underscoring that a substantial subset of patients develop the syndrome without an obvious inciting event.[7]

Epidemiology

The real incidence of Takotsubo cardiomyopathy is uncertain, and it accounts for 1 to 2% of patients suspected of having acute coronary syndrome.[8][9][10] One registry of 3265 patients with troponin-positive acute coronary syndrome reported a prevalence of 1.2% of Takotsubo cardiomyopathy, whereas a systematic review of patients presenting with suspected acute myocardial infarction reported a prevalence of 1.7 to 2.2%.[8][9] There is a strong predilection of Takotsubo cardiomyopathy to afflict postmenopausal women; however, males may have a worse prognosis if affected. In the International Takotsubo Registry study (a consortium of multiple centers across Europe and America with 1750 patients), approximately 88.9% of affected patients were women, and the mean age was 66.4 years.[7][11]

Pathophysiology

The precise pathophysiologic mechanism underlying Takotsubo cardiomyopathy remains elusive. Various hypotheses have been postulated and include elevated levels of circulating plasma catecholamines and their circulating metabolites due to underlying stress, microvascular dysfunction or microcirculatory disorder, inflammation, estrogen deficiency, spasm of the epicardial coronary vessels, and aborted myocardial infarction.[12][13] The catecholamine hypothesis is the most widely accepted pathophysiologic mechanism of Takotsubo cardiomyopathy, and elevated levels (2- to 3-fold elevation) of plasma catecholamines and neuropeptides (norepinephrine, epinephrine, and dopamine) have been observed in patients with Takotsubo cardiomyopathy. 

Catecholamines can cause microvascular spasms, dysfunction, myocardial stunning, or direct myocardial injury. Estrogen exerts protective effects on the cardiovascular system, including vasodilation, protection against atherosclerosis, and endothelial dysfunction. Therefore, postmenopausal women exhibit exaggerated vasoconstriction, altered endothelium-dependent vasodilatation, and sympathetic activation in response to psychosocial stress.[14][15]

The role of inflammation in Takotsubo cardiomyopathy is depicted by cardiac magnetic resonance imaging, which shows myocardial edema, necrosis, fibrosis, and late gadolinium enhancement.[16] Coexisting cases of myocarditis, pericarditis, or autoimmune conditions such as systemic lupus erythematosus or Sjogren syndrome have been described in the literature, suggesting that chronic inflammatory conditions with acute flares may provide a substrate for the emergence of Takotsubo cardiomyopathy.[17][18][19] Microvascular dysfunction is demonstrated by abnormal coronary flow reserve, thrombolysis in myocardial infarction frame count, perfusion grade, and quantitative flow ratio.[20][21][22][23][24] 

Impaired microvascular function has also been demonstrated by measuring the index of microvascular resistance using a pressure wire introduced into the coronary arteries.[25] There is some evidence that the prevalence of diabetes mellitus is low among patients with Takotsubo cardiomyopathy, suggesting that blunting of the autonomic response in diabetes may have a protective effect against the development of Takotsubo cardiomyopathy, the so-called "diabetes paradox."[26][27][28][29]

Histopathology

The available evidence remains limited; however, the published data do indicate that myocardial histology compatible with catecholamine-mediated injury has been described, including, but not restricted to, the following patterns: interstitial fibrosis accompanied by inflammatory cellular infiltrates; interstitial fibrosis in the absence of demonstrable cellular infiltration; mononuclear inflammatory infiltrates with contraction band necrosis; and, in some cases, no histopathologic features supporting myocarditis.[30][31][32][33]

History and Physical

Takotsubo cardiomyopathy typically presents with a clinical picture that closely mimics acute coronary syndrome, most commonly characterized by acute-onset chest pain and/or dyspnea, frequently following a recent emotional or physical stressor. A careful history is essential and should specifically probe for recent triggers such as bereavement, interpersonal conflict, major medical illness, or other significant stressors. However, a subset of patients will not report a clear precipitant.

In addition to classic ischemic-type symptoms, some patients may present with manifestations of acute heart failure, including orthopnea, paroxysmal nocturnal dyspnea, and peripheral edema. Electrical instability is also well described, and patients may present with tachyarrhythmias, bradyarrhythmias, or even sudden cardiac arrest. Neurologic symptoms, including transient ischemic attack or stroke-like presentations, may occur secondary to embolization from a left ventricular apical thrombus. Importantly, approximately 10% of patients with stress cardiomyopathy develop cardiogenic shock, underscoring the potential for rapid clinical deterioration despite the typically reversible nature of the condition.[6]

On physical examination, findings are variable and depend on the severity of ventricular dysfunction and the presence of complications. Patients may appear hemodynamically stable or exhibit signs of shock, including hypotension, altered mentation, and evidence of end-organ hypoperfusion. Pulmonary examination may reveal rales consistent with pulmonary edema in cases of acute heart failure.

Cardiac auscultation may reveal a late-peaking systolic murmur, which may indicate dynamic left ventricular outflow tract obstruction and is often accompanied by hyperdynamic basal contraction and apical ballooning on imaging. In some cases, acute severe mitral regurgitation may be present, contributing to hemodynamic instability and pulmonary congestion. Overall, the physical examination plays a critical role in identifying complications such as heart failure, left ventricular outflow tract obstruction, and valvular dysfunction, all of which have important implications for immediate management and risk stratification.

Evaluation

Takotsubo cardiomyopathy is fundamentally a diagnosis of exclusion and should only be confirmed after acute coronary syndrome, particularly ST-elevation myocardial infarction (STEMI), has been definitively ruled out. Accordingly, initial evaluation mirrors that of any patient presenting with suspected acute coronary syndrome and includes urgent electrocardiography (ECG) and measurement of cardiac biomarkers. ECG findings in Takotsubo cardiomyopathy are frequently abnormal but often misleading, as patients may demonstrate ST-segment elevations, most commonly in the anterior precordial leads, T-wave inversions, and modest elevations in cardiac troponin, closely mimicking acute myocardial infarction.

Further characterization of ECG findings reinforces the dynamic nature of the disease process. Similar to the staged ECG evolution seen in pericarditis, Takotsubo cardiomyopathy may demonstrate sequential changes, although not all patients progress through each stage.[34] Stage 1 is marked by ST-segment elevation, followed by normalization in stage 2, development of T-wave inversions in stage 3, and eventual normalization or, less commonly, persistence of T-wave abnormalities in stage 4.

Overlap between stages is common, and variability in presentation underscores the importance of integrating clinical, ECG, biomarker, and imaging data when establishing the diagnosis. Notably, significant QTc prolongation in the subacute phase is common and confers an increased risk for torsades de pointes and other ventricular arrhythmias. Recognition of this evolving pattern can provide an important diagnostic clue and has been incorporated into diagnostic frameworks (see Image. Mid-Ventricular Cardiomyopathy, Electrocardiograph).

Clinical suspicion for Takotsubo cardiomyopathy should be heightened in adults, particularly postmenopausal women, who present with features suggestive of acute coronary syndrome but demonstrate a discordance between the severity of symptoms or electrocardiographic abnormalities and the relatively modest elevation in cardiac biomarkers.[35][36][37] Definitive evaluation requires coronary angiography, which characteristically reveals the absence of obstructive coronary artery disease or acute plaque rupture. Several diagnostic schemas have been proposed, including the Mayo Clinic criteria and the International Takotsubo (InterTAK) Diagnostic Criteria.[38] The most widely used framework remains the Mayo Clinic diagnostic criteria, all of which must be met for diagnosis.[39][40] These include:

• Transient left ventricular systolic dysfunction characterized by hypokinesis, akinesis, or dyskinesis, typically involving the midventricular segments with or without apical involvement, and extending beyond a single coronary vascular territory
• Absence of obstructive coronary artery disease or angiographic evidence of acute plaque rupture
• New ECG abnormalities (ST-segment elevation and/or T-wave inversion) accompanied by a mild to moderate rise in cardiac troponin levels
• Exclusion of alternative diagnoses such as myocarditis or pheochromocytoma

Other Diagnostic Findings

Laboratory evaluation in Takotsubo cardiomyopathy typically reveals only modest elevations in cardiac biomarkers despite often striking clinical and ECG abnormalities. Cardiac troponins and creatine kinase-MB are elevated but generally to a lesser degree than would be expected in a large myocardial infarction. In the International Takotsubo Registry, the median initial troponin level was approximately 7.7 times the upper limit of normal.

In contrast, levels of brain natriuretic peptide (BNP) or N-terminal pro-BNP are frequently markedly elevated. They may exceed those observed in matched cohorts of patients with acute coronary syndrome (median 5.89 vs 2.91 times the upper limit of normal), reflecting the degree of myocardial stress and ventricular dysfunction.[7] This disproportion, relatively modest troponin elevation with significantly elevated natriuretic peptides, can serve as a useful diagnostic clue in the appropriate clinical context.

Transthoracic echocardiography (TTE) is a cornerstone of evaluation and typically demonstrates characteristic regional wall motion abnormalities that extend beyond a single coronary artery territory (see Image. Mid-Ventricular Cardiomyopathy in Diastole, Echocardiography, and see Image. Mid-Ventricular Cardiomyopathy in Systole, Echocardiography). The classic (apical) variant, present in approximately 80% of patients in the International Takotsubo Registry, is characterized by apical systolic ballooning with hypokinesis or akinesis of the mid and apical segments and compensatory hyperkinesis of the basal segments.[7] Several atypical variants have also been described, including midventricular hypokinesis (14.6%), basal (reverse Takotsubo) hypokinesis (2.2%), focal hypokinesis, most commonly involving the anterolateral wall (1.5%), and, less commonly, global hypokinesis.[7] Overall, left ventricular systolic function is typically reduced, and right ventricular involvement may also be present, which has prognostic implications. Echocardiography additionally allows for identification of complications such as left ventricular outflow tract obstruction, mitral regurgitation, and ventricular thrombus.

Cardiovascular MRI provides complementary diagnostic value, particularly when echocardiographic windows are suboptimal or when coexisting coronary artery disease complicates interpretation. Cardiovascular MRI enables detailed assessment of ventricular morphology and function, delineates the full extent of myocardial involvement, and assists in differentiating Takotsubo cardiomyopathy from alternative diagnoses such as myocarditis or myocardial infarction with nonobstructive coronary arteries. Typical findings include myocardial edema without a corresponding pattern of late gadolinium enhancement, although in some cases, subtle enhancement reflecting necrosis or fibrosis may be observed. Additionally, cardiovascular MRI can identify complications such as ventricular thrombus and quantify right ventricular involvement.

Radionuclide myocardial perfusion imaging is generally not indicated in the acute evaluation of Takotsubo cardiomyopathy. Most patients present with features concerning acute coronary syndrome and appropriately proceed to invasive coronary angiography. However, in selected patients with low- to intermediate-risk non–ST-elevation presentations, radionuclide imaging may play a role in further risk stratification and evaluation.

Cardiac catheterization with coronary angiography remains the definitive diagnostic modality when Takotsubo cardiomyopathy presents as STEMI or troponin-positive acute coronary syndrome. Angiographic findings characteristically demonstrate the absence of obstructive coronary artery disease or reveal only mild to moderate atherosclerosis without evidence of acute plaque rupture (see Image. Mid-Ventricular Cardiomyopathy Left Heart Catheterization, Echocardiograph).[41] When integrated with ventriculography or adjunctive imaging, these findings help confirm the diagnosis, particularly when accompanied by the characteristic pattern of transient ventricular dysfunction.

Treatment / Management

Although Takotsubo cardiomyopathy is thought to be a benign condition, recent observation data suggest that cardiogenic shock and death rates are comparable to those of patients with acute coronary syndrome. Thus, initial management should focus on identifying and closely monitoring patients at risk for serious complications. Predictors of adverse in-hospital outcomes include physical triggers, acute neurologic or psychiatric diseases, an initial troponin greater than 10 times the upper reference limit, and an admission left ventricular ejection fraction less than 45%.[7] Men have an up to a 3-fold increased death rate and major adverse cardiac and cerebrovascular events, primarily due to an increased burden of comorbidities.[42] 

Guidelines for the management of Takotsubo cardiomyopathy are lacking because there are no prospective randomized data; thus, management is based on clinical experience and expert consensus (evidence level C). Since the initial presentation of takotsubo cardiomyopathy is similar to an acute coronary syndrome, the initial treatment involves aspirin, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, lipid-lowering agents, and coronary angiography to rule out obstructive coronary artery disease.[43] The therapy is guided by the patient’s clinical presentation and hemodynamic status. 

In stable individuals, treatment modalities include cardioselective beta-blockers and ACE inhibitors for a short period of around 3 to 6 months, with serial imaging studies to determine wall motion abnormalities and ventricular ejection fraction to determine progression or improvement. Anticoagulation is usually reserved for those with documented ventricular thrombus or evidence of embolic events, which occur in 5% of patients with Takotsubo cardiomyopathy. Patients with more unstable hemodynamics or those who present in cardiogenic shock in the absence of left ventricular outflow obstruction should be treated with inotropes. Alternatively, patients may derive further benefit from mechanical hemodynamic support with an intra-aortic balloon pump or, rarely, left ventricular assist devices. If left ventricular outflow tract obstruction is present with cardiogenic shock, inotropes should be avoided; phenylephrine is the pressor agent of choice and is often combined with beta-blockers.

Differential Diagnosis

The main differentials to consider include:

• Acute coronary syndrome
• Cocaine-related coronary syndrome
• Coronary artery spasm
• Esophageal spasm
• Myocarditis
• Pericarditis
• Pheochromocytoma

Prognosis

Although most patients with Takotsubo cardiomyopathy recover, the risk of complications among those hospitalized is similar to that of acute myocardial infarction. The reported mortality among patients with Takotsubo cardiomyopathy ranges from 0% to 8%, with a mortality of 4.1% in the International Takotsubo Registry study.[7][40][44][45][46] The prognosis of Takotsubo cardiomyopathy depends on its underlying trigger, and Takotsubo cardiomyopathy should be subclassified into primary and secondary forms. Primary Takotsubo cardiomyopathy occurs due to emotional/psychological stimuli, and secondary forms occur due to physical factors in a hospital setting, such as sepsis, trauma, surgery, or other critical illnesses, a phenomenon that was evident during the COVID-19 pandemic. Secondary Takotsubo cardiomyopathy is associated with worse in-hospital and long-term outcomes.[47][48][49][50]

Several clinical and imaging characteristics are now consistently associated with an unfavorable prognosis in Takotsubo syndrome. These high-risk features include advanced age, male sex, the presence of significant physical stressors (such as sepsis or malignancy), low systolic blood pressure, pulmonary edema, depressed left ventricular ejection fraction, biventricular involvement, left ventricular outflow tract obstruction, significant mitral regurgitation, mural thrombus formation, coexistent coronary artery disease, persistent ST-segment elevation, and marked prolongation of the QT interval.[51] Crucially, large registries and observational cohorts have shown that, over the long term, patients with Takotsubo syndrome experience excess mortality, with survival rates comparable to or even worse than those observed after an acute myocardial infarction. Risk stratification in this condition, therefore, remains both essential and inherently challenging, but it is also an area of active development. Notably, emerging clinical and electrocardiographic prediction models that incorporate artificial intelligence techniques may substantially support the refinement of prognostic assessment in this population.[5][29][5][52][53]

Complications

The main complications include left ventricular outflow tract obstruction, life-threatening ventricular arrhythmias, paroxysmal or persistent atrial fibrillation, hypotension, low output syndrome, cardiogenic shock, heart failure, and thromboembolism. The incidence of the second event in patients who survive the initial event is about 5% and mostly occurs 3 weeks to 3.8 years after the first event.[54]

Deterrence and Patient Education

Given the multifactorial and incompletely understood etiology of Takotsubo cardiomyopathy, primary prevention is not always feasible; however, targeted risk mitigation and patient education can reduce recurrence risk and improve overall outcomes. A central component of deterrence involves identifying and addressing precipitating stressors. Patients should be counseled on the strong association between intense emotional or physical stress and disease onset and encouraged to adopt structured stress-reduction strategies, including cognitive behavioral therapy, mindfulness-based interventions, and, when appropriate, formal mental health support.

Screening for and addressing comorbid psychiatric conditions, such as anxiety and depression, as well as social determinants, including domestic abuse, is essential. Patients should also be advised to avoid stimulant substances such as cocaine and amphetamines and to ensure optimal management of acute and chronic medical conditions that may serve as physiologic stressors. Although evidence remains limited, continuation of beta-blockers and other guideline-directed medical therapies may be considered in select patients to mitigate adrenergic surges, though recurrence can still occur.

Patient education should emphasize that most individuals recover well after a Takotsubo event, although recovery timelines vary. Some patients experience near-complete recovery within weeks, whereas others may require several months, and emerging data suggest that a subset may have persistent or subclinical cardiac dysfunction. Accordingly, patients should be counseled to adopt a recovery pace tailored to their individual clinical status rather than adhering to a fixed timeline. Clearly communicating that, despite the generally favorable prognosis, serious complications, including heart failure, arrhythmias, thromboembolism, and cardiogenic shock, can occur, particularly in the acute phase, is important. Patients should be educated on recognizing early warning symptoms such as chest pain, dyspnea, or syncope and instructed to seek immediate medical attention, as recurrence can closely mimic acute coronary syndrome.

Structured follow-up is critical and typically includes repeat echocardiography to document recovery of ventricular function, along with reassessment of ongoing symptoms and risk factors. A multidisciplinary approach is essential, involving cardiology, primary care, and mental health professionals. Cardiac rehabilitation should be strongly considered, as it provides supervised physical conditioning, education, and psychosocial support during recovery. Additionally, patients may benefit from participation in Takotsubo-specific support groups, which can offer peer support and improve coping strategies. Nursing staff, particularly cardiac nurses, play a key role in coordinating these resources, reinforcing education, and guiding patients through recovery to optimize long-term outcomes.

Enhancing Healthcare Team Outcomes

Effective management of Takotsubo cardiomyopathy requires a coordinated, multidisciplinary approach centered on rapid recognition, risk stratification, and avoidance of potentially harmful interventions. Physicians and advanced practitioners must maintain a high index of suspicion in patients presenting with apparent acute coronary syndrome but discordant biomarker elevation and imaging findings, ensuring timely activation of acute coronary syndrome pathways while concurrently considering alternative diagnoses. Early use of echocardiography and coronary angiography is critical to establish the diagnosis and guide management.

Strategic decision-making includes careful hemodynamic assessment, particularly in patients with cardiogenic shock or left ventricular outflow tract obstruction, where standard therapies such as inotropes may be contraindicated. Continuous cardiac monitoring is essential to detect arrhythmias, especially in the setting of QT prolongation. Clear, structured communication between emergency medicine, cardiology, and critical care teams is vital to ensure diagnostic accuracy and prevent inappropriate therapies.

Interprofessional collaboration is central to optimizing patient-centered outcomes. Nursing staff play a key role in continuous hemodynamic and rhythm monitoring, early identification of clinical deterioration, and reinforcement of patient education. Pharmacists contribute by optimizing medication regimens, avoiding QT-prolonging agents, and ensuring safe use of anticoagulation when left ventricular thrombus is present or suspected.

Care coordination should extend beyond the acute setting, involving cardiac rehabilitation services, mental health professionals, and primary care providers to address precipitating stressors and support recovery. Social workers and case managers may assist with psychosocial needs, including access to support systems and follow-up care. This integrated, team-based approach enhances patient safety, reduces complications, and improves both short- and long-term outcomes in patients with Takotsubo cardiomyopathy.

Review Questions

• Access free multiple choice questions on this topic.
• Access free CME on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Baltzer Nielsen S, Stanislaus S, Saunamäki K, Grøndahl C, Banner J, Jørgensen MB. Can acute stress be fatal? A systematic cross-disciplinary review. Stress. 2019 May;22(3):286-294. [PubMed: 30767612]

2.

Nandal S, Castles A, Asrar Ul Haq M, van Gaal W. Takotsubo cardiomyopathy triggered by status epilepticus: case report and literature review. BMJ Case Rep. 2019 Jan 29;12(1) [PMC free article: PMC6352843] [PubMed: 30700451]

3.

Khalid N, Ahmad SA, Shlofmitz E, Umer A, Chhabra L. Sex disparities and microvascular dysfunction. Int J Cardiol. 2019 May 01;282:16. [PubMed: 30851944]

4.

Khalid N, Ahmad SA, Shlofmitz E, Chhabra L. Racial and gender disparities among patients with Takotsubo syndrome. Clin Cardiol. 2019 Jan;42(1):19. [PMC free article: PMC6436496] [PubMed: 30525217]

5.

Kato K, Di Vece D, Kitagawa M, Yamamoto K, Miyakoda K, Aoki S, Goto H, Kitahara H, Kobayashi Y, Templin C. Clinical characteristics and outcomes in takotsubo syndrome -Review of insights from the InterTAK Registry. J Cardiol. 2025 Apr;85(4):263-267. [PubMed: 39892867]

6.

Templin C, Ghadri JR, Diekmann J, Napp LC, Bataiosu DR, Jaguszewski M, Cammann VL, Sarcon A, Geyer V, Neumann CA, Seifert B, Hellermann J, Schwyzer M, Eisenhardt K, Jenewein J, Franke J, Katus HA, Burgdorf C, Schunkert H, Moeller C, Thiele H, Bauersachs J, Tschöpe C, Schultheiss HP, Laney CA, Rajan L, Michels G, Pfister R, Ukena C, Böhm M, Erbel R, Cuneo A, Kuck KH, Jacobshagen C, Hasenfuss G, Karakas M, Koenig W, Rottbauer W, Said SM, Braun-Dullaeus RC, Cuculi F, Banning A, Fischer TA, Vasankari T, Airaksinen KE, Fijalkowski M, Rynkiewicz A, Pawlak M, Opolski G, Dworakowski R, MacCarthy P, Kaiser C, Osswald S, Galiuto L, Crea F, Dichtl W, Franz WM, Empen K, Felix SB, Delmas C, Lairez O, Erne P, Bax JJ, Ford I, Ruschitzka F, Prasad A, Lüscher TF. Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. N Engl J Med. 2015 Sep 03;373(10):929-38. [PubMed: 26332547]

7.

Kurowski V, Kaiser A, von Hof K, Killermann DP, Mayer B, Hartmann F, Schunkert H, Radke PW. Apical and midventricular transient left ventricular dysfunction syndrome (tako-tsubo cardiomyopathy): frequency, mechanisms, and prognosis. Chest. 2007 Sep;132(3):809-16. [PubMed: 17573507]

8.

Gianni M, Dentali F, Grandi AM, Sumner G, Hiralal R, Lonn E. Apical ballooning syndrome or takotsubo cardiomyopathy: a systematic review. Eur Heart J. 2006 Jul;27(13):1523-9. [PubMed: 16720686]

9.

Prasad A, Dangas G, Srinivasan M, Yu J, Gersh BJ, Mehran R, Stone GW. Incidence and angiographic characteristics of patients with apical ballooning syndrome (takotsubo/stress cardiomyopathy) in the HORIZONS-AMI trial: an analysis from a multicenter, international study of ST-elevation myocardial infarction. Catheter Cardiovasc Interv. 2014 Feb 15;83(3):343-8. [PubMed: 22121008]

10.

Schweiger V, Cammann VL, Crisci G, Gilhofer T, Schlenker R, Niederseer D, Chen S, Ebrahimi R, Wenzl F, Würdinger M, Citro R, Vecchione C, Gili S, Neuhaus M, Franke J, Meder B, Jaguszewski M, Noutsias M, Knorr M, Jansen T, D'Ascenzo F, Dichtl W, von Lewinski D, Burgdorf C, Kherad B, Tschöpe C, Sarcon A, Shinbane J, Rajan L, Michels G, Pfister R, Cuneo A, Jacobshagen C, Karakas M, Koenig W, Pott A, Meyer P, Roffi M, Banning A, Wolfrum M, Cuculi F, Kobza R, Fischer TA, Vasankari T, Airaksinen KEJ, Napp LC, Dworakowski R, MacCarthy P, Kaiser C, Osswald S, Galiuto L, Chan C, Bridgman P, Beug D, Delmas C, Lairez O, Gilyarova E, Shilova A, Gilyarov M, El-Battrawy I, Akin I, Poledniková K, Toušek P, Winchester DE, Massoomi M, Galuszka J, Ukena C, Poglajen G, Carrilho-Ferreira P, Hauck C, Paolini C, Bilato C, Kobayashi Y, Kato K, Ishibashi I, Himi T, Din J, Al-Shammari A, Prasad A, Rihal CS, Liu K, Schulze PC, Bianco M, Jörg L, Rickli H, Pestana G, Nguyen TH, Böhm M, Maier LS, Pinto FJ, Widimský P, Felix SB, Braun-Dullaeus RC, Rottbauer W, Hasenfuß G, Pieske BM, Schunkert H, Budnik M, Opolski G, Thiele H, Bauersachs J, Horowitz JD, Di Mario C, Kong W, Dalakoti M, Imori Y, Münzel T, Liberale L, Montecucco F, Bax JJ, Crea F, Ruschitzka F, Lüscher TF, Ghadri JR, Bossone E, Templin C, Di Vece D. Temporal Trends in Takotsubo Syndrome: Results From the International Takotsubo Registry. J Am Coll Cardiol. 2024 Sep 24;84(13):1178-1189. [PubMed: 39217551]

11.

Khalid N, Shams P, Shlofmitz E, Chhabra L. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Dec 11, 2024. Pathophysiology of Takotsubo Syndrome. [PubMed: 30844187]

12.

Pelliccia F, Kaski JC, Crea F, Camici PG. Pathophysiology of Takotsubo Syndrome. Circulation. 2017 Jun 13;135(24):2426-2441. [PubMed: 28606950]

13.

Martin EA, Prasad A, Rihal CS, Lerman LO, Lerman A. Endothelial function and vascular response to mental stress are impaired in patients with apical ballooning syndrome. J Am Coll Cardiol. 2010 Nov 23;56(22):1840-6. [PMC free article: PMC3786427] [PubMed: 21087714]

14.

Lyon AR, Citro R, Schneider B, Morel O, Ghadri JR, Templin C, Omerovic E. Pathophysiology of Takotsubo Syndrome: JACC State-of-the-Art Review. J Am Coll Cardiol. 2021 Feb 23;77(7):902-921. [PubMed: 33602474]

15.

Eitel I, von Knobelsdorff-Brenkenhoff F, Bernhardt P, Carbone I, Muellerleile K, Aldrovandi A, Francone M, Desch S, Gutberlet M, Strohm O, Schuler G, Schulz-Menger J, Thiele H, Friedrich MG. Clinical characteristics and cardiovascular magnetic resonance findings in stress (takotsubo) cardiomyopathy. JAMA. 2011 Jul 20;306(3):277-86. [PubMed: 21771988]

16.

Khalid N, Ahmad SA, Umer A, Chhabra L. Takotsubo cardiomyopathy and myopericarditis: Unraveling the inflammatory hypothesis. Int J Cardiol. 2015 Oct 01;196:168-9. [PubMed: 26114444]

17.

Khalid N, Chhabra L. Takotsubo Cardiomyopathy and Viral Myopericarditis: An Association Which Should be Considered in the Differential Diagnosis. Angiology. 2016 Apr;67(4):398. [PubMed: 25969569]

18.

Chhabra L, Khalid N, Kluger J, Spodick DH. Lupus myopericarditis as a preceding stressor for takotsubo cardiomyopathy. Proc (Bayl Univ Med Cent). 2014 Oct;27(4):327-30. [PMC free article: PMC4255855] [PubMed: 25484500]

19.

Khalid N. Microcirculatory disorder hypothesis in Takotsubo cardiomyopathy. Int J Cardiol. 2015 Sep 15;195:29. [PubMed: 26022795]

20.

Khalid N, Chhabra L. Takotsubo cardiomyopathy and microcirculatory dysfunction. Nat Rev Cardiol. 2015 Aug;12(8):497. [PubMed: 26076951]

21.

Fazio G, Sarullo FM, Novo G, Evola S, Lunetta M, Barbaro G, Sconci F, Azzarelli S, Akashi Y, Fedele F, Novo S. Tako-tsubo cardiomyopathy and microcirculation. J Clin Monit Comput. 2010 Apr;24(2):101-5. [PubMed: 20058057]

22.

Khalid N, Ikram S. Coronary flow assessment in Takotsubo cardiomyopathy with TIMI frame count. Int J Cardiol. 2015 Oct 15;197:208. [PubMed: 26142964]

23.

Khalid N, Ahmad SA, Umer A. Coronary flow reserve assessment via invasive and noninvasive means in Takotsubo cardiomyopathy. Int J Cardiol. 2016 Jan 01;202:573. [PubMed: 26447665]

24.

Rivero F, Cuesta J, García-Guimaraes M, Bastante T, Alvarado T, Antuña P, Alfonso F. Time-Related Microcirculatory Dysfunction in Patients With Takotsubo Cardiomyopathy. JAMA Cardiol. 2017 Jun 01;2(6):699-700. [PMC free article: PMC5815019] [PubMed: 28273298]

25.

Khalid N, Ahmad SA, Umer A, Chhabra L. Role of Microcirculatory Disturbances and Diabetic Autonomic Neuropathy in Takotsubo Cardiomyopathy. Crit Care Med. 2015 Nov;43(11):e527. [PubMed: 26468716]

26.

Bill V, El-Battrawy I, Behnes M, Baumann S, Becher T, Elmas E, Hoffmann U, Haghi D, Fastner C, Kuschyk J, Papavassiliu T, Borggrefe M, Akin I. "Diabetes paradox" in Takotsubo Cardiomyopathy. Int J Cardiol. 2016 Dec 01;224:88-89. [PubMed: 27636833]

27.

Khalid N, Chhabra L, Ahmad SA, Sareen P, Spodick DH. Autonomic Dysfunction and Takotsubo Cardiomyopathy. Am J Med. 2015 Nov;128(11):e45-6. [PubMed: 26500214]

28.

Matta AG, Carrié D. Epidemiology, Pathophysiology, Diagnosis, and Principles of Management of Takotsubo Cardiomyopathy: A Review. Med Sci Monit. 2023 Mar 06;29:e939020. [PMC free article: PMC9999670] [PubMed: 36872594]

29.

Karch SB, Billingham ME. Myocardial contraction bands revisited. Hum Pathol. 1986 Jan;17(1):9-13. [PubMed: 2417934]

30.

Fineschi V, Silver MD, Karch SB, Parolini M, Turillazzi E, Pomara C, Baroldi G. Myocardial disarray: an architectural disorganization linked with adrenergic stress? Int J Cardiol. 2005 Mar 18;99(2):277-82. [PubMed: 15749187]

31.

Wittstein IS, Thiemann DR, Lima JA, Baughman KL, Schulman SP, Gerstenblith G, Wu KC, Rade JJ, Bivalacqua TJ, Champion HC. Neurohumoral features of myocardial stunning due to sudden emotional stress. N Engl J Med. 2005 Feb 10;352(6):539-48. [PubMed: 15703419]

32.

Kurisu S, Sato H, Kawagoe T, Ishihara M, Shimatani Y, Nishioka K, Kono Y, Umemura T, Nakamura S. Tako-tsubo-like left ventricular dysfunction with ST-segment elevation: a novel cardiac syndrome mimicking acute myocardial infarction. Am Heart J. 2002 Mar;143(3):448-55. [PubMed: 11868050]

33.

Chhabra L, Khalid N, Sareen P. Extremely Low Prevalence of Takotsubo Cardiomyopathy and Transient Cardiac Dysfunction in Stroke Patients With T-wave Abnormalities. Am J Cardiol. 2019 Mar 15;123(6):1009. [PubMed: 30661722]

34.

Medina de Chazal H, Del Buono MG, Keyser-Marcus L, Ma L, Moeller FG, Berrocal D, Abbate A. Stress Cardiomyopathy Diagnosis and Treatment: JACC State-of-the-Art Review. J Am Coll Cardiol. 2018 Oct 16;72(16):1955-1971. [PMC free article: PMC7058348] [PubMed: 30309474]

35.

Cusmà-Piccione M, Longobardo L, Oteri A, Manganaro R, Di Bella G, Carerj S, Khandheria BK, Zito C. Takotsubo cardiomyopathy: queries of the current era. J Cardiovasc Med (Hagerstown). 2018 Nov;19(11):624-632. [PubMed: 30234685]

36.

Manfredini R, Fabbian F, De Giorgi A, Cappadona R, Zucchi B, Storari A, Rodriguez Borrego MA, Carmona Torres JM, Lopez Soto PJ. Takotsubo syndrome and dialysis: an uncommon association? J Int Med Res. 2018 Nov;46(11):4399-4406. [PMC free article: PMC6259368] [PubMed: 30178683]

37.

Ghadri JR, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, Cammann VL, Crea F, Galiuto L, Desmet W, Yoshida T, Manfredini R, Eitel I, Kosuge M, Nef HM, Deshmukh A, Lerman A, Bossone E, Citro R, Ueyama T, Corrado D, Kurisu S, Ruschitzka F, Winchester D, Lyon AR, Omerovic E, Bax JJ, Meimoun P, Tarantini G, Rihal C, Y-Hassan S, Migliore F, Horowitz JD, Shimokawa H, Lüscher TF, Templin C. International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology. Eur Heart J. 2018 Jun 07;39(22):2032-2046. [PMC free article: PMC5991216] [PubMed: 29850871]

38.

Prasad A, Lerman A, Rihal CS. Apical ballooning syndrome (Tako-Tsubo or stress cardiomyopathy): a mimic of acute myocardial infarction. Am Heart J. 2008 Mar;155(3):408-17. [PubMed: 18294473]

39.

Bybee KA, Kara T, Prasad A, Lerman A, Barsness GW, Wright RS, Rihal CS. Systematic review: transient left ventricular apical ballooning: a syndrome that mimics ST-segment elevation myocardial infarction. Ann Intern Med. 2004 Dec 07;141(11):858-65. [PubMed: 15583228]

40.

Zghyer F, Botheju WSP, Kiss JE, Michos ED, Corretti MC, Mukherjee M, Hays AG. Cardiovascular Imaging in Stress Cardiomyopathy (Takotsubo Syndrome). Front Cardiovasc Med. 2021;8:799031. [PMC free article: PMC8831380] [PubMed: 35155609]

41.

Brinjikji W, El-Sayed AM, Salka S. In-hospital mortality among patients with takotsubo cardiomyopathy: a study of the National Inpatient Sample 2008 to 2009. Am Heart J. 2012 Aug;164(2):215-21. [PubMed: 22877807]

42.

Ghadri JR, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, Cammann VL, Crea F, Galiuto L, Desmet W, Yoshida T, Manfredini R, Eitel I, Kosuge M, Nef HM, Deshmukh A, Lerman A, Bossone E, Citro R, Ueyama T, Corrado D, Kurisu S, Ruschitzka F, Winchester D, Lyon AR, Omerovic E, Bax JJ, Meimoun P, Tarantini G, Rihal C, Y-Hassan S, Migliore F, Horowitz JD, Shimokawa H, Lüscher TF, Templin C. International Expert Consensus Document on Takotsubo Syndrome (Part II): Diagnostic Workup, Outcome, and Management. Eur Heart J. 2018 Jun 07;39(22):2047-2062. [PMC free article: PMC5991205] [PubMed: 29850820]

43.

Tsuchihashi K, Ueshima K, Uchida T, Oh-mura N, Kimura K, Owa M, Yoshiyama M, Miyazaki S, Haze K, Ogawa H, Honda T, Hase M, Kai R, Morii I., Angina Pectoris-Myocardial Infarction Investigations in Japan. Transient left ventricular apical ballooning without coronary artery stenosis: a novel heart syndrome mimicking acute myocardial infarction. Angina Pectoris-Myocardial Infarction Investigations in Japan. J Am Coll Cardiol. 2001 Jul;38(1):11-8. [PubMed: 11451258]

44.

Sharkey SW, Lesser JR, Zenovich AG, Maron MS, Lindberg J, Longe TF, Maron BJ. Acute and reversible cardiomyopathy provoked by stress in women from the United States. Circulation. 2005 Feb 01;111(4):472-9. [PubMed: 15687136]

45.

Akashi YJ, Musha H, Kida K, Itoh K, Inoue K, Kawasaki K, Hashimoto N, Miyake F. Reversible ventricular dysfunction takotsubo cardiomyopathy. Eur J Heart Fail. 2005 Dec;7(7):1171-6. [PubMed: 16397924]

46.

Chhabra L, Sareen P, Mwansa V, Khalid N. Mortality in Takotsubo cardiomyopathy should also be accounted based on predisposing etiology. Ann Noninvasive Electrocardiol. 2019 Jul;24(4):e12664. [PMC free article: PMC6931614] [PubMed: 31155779]

47.

Khalid N, Ahmad SA, Shlofmitz E, Umer A, Chhabra L. Takotsubo cardiomyopathy: prognostication is affected by the underlying trigger. J Cardiovasc Med (Hagerstown). 2019 Jun;20(6):409-410. [PubMed: 31045855]

48.

Khalid N, Ikram S. Microvascular dysfunction in Takotsubo cardiomyopathy: Prognostic implications. Int J Cardiol. 2015 Dec 15;201:58-9. [PubMed: 26288330]

49.

Jabri A, Kalra A, Kumar A, Alameh A, Adroja S, Bashir H, Nowacki AS, Shah R, Khubber S, Kanaa'N A, Hedrick DP, Sleik KM, Mehta N, Chung MK, Khot UN, Kapadia SR, Puri R, Reed GW. Incidence of Stress Cardiomyopathy During the Coronavirus Disease 2019 Pandemic. JAMA Netw Open. 2020 Jul 01;3(7):e2014780. [PMC free article: PMC7348683] [PubMed: 32644140]

50.

Movahed MR, Javanmardi E, Hashemzadeh M. High Mortality and Complications in Patients Admitted With Takotsubo Cardiomyopathy With More Than Double Mortality in Men Without Improvement in Outcome Over the Years. J Am Heart Assoc. 2025 May 20;14(10):e037219. [PMC free article: PMC12184606] [PubMed: 40365782]

51.

Kosek-Nikołajczuk M, Borowiak E, Piatkowski R, Grabowski M, Budnik M. Long-Term Prognosis, Risk Assessment, and Management of Patients Diagnosed with Takotsubo Syndrome: A Narrative Review. J Pers Med. 2025 Sep 04;15(9) [PMC free article: PMC12470797] [PubMed: 41003128]

52.

Yalta K, Madias JE, Kounis NG, Y-Hassan S, Polovina M, Altay S, Mebazaa A, Yilmaz MB, Lopatin Y, Mamas MA, Gil RJ, Thamman R, Almaghraby A, Bozkurt B, Bajraktari G, Fink T, Traykov V, Manzo-Silberman S, Mirzoyev U, Sokolovic S, Kipiani ZV, Linde C, Seferovic PM. Takotsubo Syndrome: An International Expert Consensus Report on Practical Challenges and Specific Conditions (Part-2: Specific Entities, Risk Stratification and Challenges After Recovery). Balkan Med J. 2024 Oct 31;41(6):442-457. [PMC free article: PMC11589209] [PubMed: 39417538]

53.

Sharkey SW, Windenburg DC, Lesser JR, Maron MS, Hauser RG, Lesser JN, Haas TS, Hodges JS, Maron BJ. Natural history and expansive clinical profile of stress (tako-tsubo) cardiomyopathy. J Am Coll Cardiol. 2010 Jan 26;55(4):333-41. [PubMed: 20117439]

Disclosure: Mohamed Alahmadi declares no relevant financial relationships with ineligible companies.

Disclosure: Vijai Tivakaran declares no relevant financial relationships with ineligible companies.